Analyst Price Targets — GERN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2025 10:13 am | Peter Lawson | Barclays | $4.00 | $1.61 | TheFly | Geron price target lowered to $4 from $9 at Barclays |
| November 5, 2024 11:02 am | Emily Bodnar | H.C. Wainwright | $8.00 | $4.24 | StreetInsider | H.C. Wainwright Starts Geron Corporation (GERN) at Buy |
| October 22, 2024 6:52 am | Kalpit Patel | B.Riley Financial | $5.50 | $3.95 | StreetInsider | B.Riley Reiterates Buy Rating on Geron Corporation (GERN) ahead of Q3 |
| September 9, 2024 6:23 am | Faisal Khurshid | Leerink Partners | $7.00 | $4.25 | TheFly | Geron initiated with an Outperform at Leerink |
| June 10, 2024 11:59 am | Corinne Jenkins | Goldman Sachs | $6.00 | $4.95 | StreetInsider | Geron Corporation (GERN) PT Raised to $6 at Goldman Sachs |
| June 10, 2024 6:39 am | Stephen Willey | Stifel Nicolaus | $7.00 | $4.59 | TheFly | Geron price target raised to $7 from $6 at Stifel |
| April 30, 2024 2:33 am | Joel Beatty | Robert W. Baird | $4.50 | $4.14 | StreetInsider | Baird Downgrades Geron Corporation (GERN) to Neutral 'on Valuation Concerns' |
| March 15, 2024 7:12 am | Gil Blum | Needham | $5.00 | $3.36 | StreetInsider | Geron Corporation (GERN) PT Raised to $5 at Needham, 'anticipate imetelstat will receive the go-ahead on or prior to its June 16 PDUFA date' |
| March 15, 2024 3:51 am | Corinne Jenkins | Goldman Sachs | $5.00 | $3.36 | StreetInsider | Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs |
| January 9, 2023 10:30 am | — | Needham | $4.00 | $2.79 | Benzinga | Needham Maintains Buy on Geron, Raises Price Target to $4 |
Latest News for GERN
Current revenue trends of Geron suggest RYTELO is primarily finding its niche in the later-line "salvage" setting, which may continue to moderate near-term growth expectations. Geron's recent strategic restructuring and workforce reductions reflect a pivot toward financial discipline as the company navigates current uptake patterns and persistent net losses. Intensifying gross-to-net pressures and complex European…
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025…
FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GERN.
U.S. House Trading
No House trades found for GERN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.